A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma - Scorecard - MDSpire

A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma

  • By

  • Sveva Castelli

  • Tim Flaadt

  • Franziska Schulze

  • Theresa M. Thole-Kliesch

  • Felix Zirngibl

  • Lena Oevermann

  • Annette Künkele

  • Kathy Astrahantseff

  • Stefanie Schulte

  • Louisa Duell

  • Joerg Fuchs

  • Thorsten Simon

  • Barbara Hero

  • Patrick Hundsdoerfer

  • Julian M. M. Rogasch

  • Peter Lang

  • Steven Warmann

  • Arend von Stackelberg

  • Johannes H. Schulte

  • Angelika Eggert

  • Hedwig E. Deubzer

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: A preliminary investigation of haploidentical stem cell transplantation using a busulfan regimen combined with GD2 antibody therapy for the management of high-risk neuroblastoma

At a Glance

CategoryDetail
Condition
Key MechanismsBusulfan/melphalan conditioning, haploidentical stem cell transplantation, GD2-directed antibody therapy
Target Population
Care Setting

Key Highlights

  • Event-free survival is <20% in very high-risk neuroblastoma patients.
  • Haploidentical stem cell transplantation (haplo-SCT) shows feasibility and effectiveness.
  • Three of five patients remained in complete remission for over 1.5 years post-transplant.
  • Further confirmation in larger controlled trials is warranted.

Guideline-Based Recommendations

Diagnosis

    Management

    • Use of haplo-SCT combined with dinutuximab beta for high-risk neuroblastoma.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Five pediatric patients with INRG stage M high-risk neuroblastoma.

        Patients received conditioning with busulfan/melphalan followed by haplo-SCT and GD2 antibody therapy.

        Clinical Best Practices

        • Ensure informed consent is obtained from parents or guardians.
        • Conduct data collection in accordance with ethical standards.

        Related Resources & Content

        Original Source(s)

        A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma

        • by Sveva Castelli, Tim Flaadt, Franziska Schulze, Theresa M. Thole-Kliesch, Felix Zirngibl, Lena Oevermann, Annette Künkele, Kathy Astrahantseff, Stefanie Schulte, Louisa Duell, Joerg Fuchs, Thorsten Simon, Barbara Hero, Patrick Hundsdoerfer, Julian M. M. Rogasch, Peter Lang, Steven Warmann, Arend von Stackelberg, Johannes H. Schulte, Angelika Eggert, Hedwig E. Deubzer

        • May 29, 2026

        Related Content

        Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

        Increased lymphoma risk in patients with systemic manifestations of Sjögren’s disease: a population-based study

        Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship